Cargando…

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials

Detalles Bibliográficos
Autores principales:	Dimosiari, Athina, Patoulias, Dimitrios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487802/ https://www.ncbi.nlm.nih.gov/pubmed/36158066 http://dx.doi.org/10.5114/amsad/150507

Ejemplares similares

Effect of COVID-19 on endothelial function evaluated with flow-mediated dilation: another prognostic marker? A meta-analysis of observational studies
por: Dimosiari, Athina, et al.
Publicado: (2022)

Anakinra or tocilizumab for prevention of COVID-19 death? A big dilemma
por: Patoulias, Dimitrios, et al.
Publicado: (2021)

Takayasu Arteritis is Associated with Impaired Arterial Stiffness: A Meta-Analysis of Observational Studies
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Intravenous pulse methylprednisolone for the treatment of severe COVID-19
por: Patoulias, Dimitrios, et al.
Publicado: (2023)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

“Weighing” the risks and benefits – Thromboprophylaxis challenges in obese COVID-19 patients
por: Rokkam, Venkata Ram Pradeep, et al.
Publicado: (2020)

Anti-Interleukins for Severe Coronavirus Disease-2019: Hype or Hope?
por: Dimosiari, Athina, et al.
Publicado: (2022)

Meta-analysis addressing the impact of sodium-glucose Co-transporter-2 inhibitors on the risk for atrial fibrillation among individuals with heart failure with preserved ejection fraction
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

How Should Concurrent Arterial and Venous Thrombosis Associated With SARS-CoV-2 Infection Be Managed?
por: Dimosiari, Athina, et al.
Publicado: (2022)

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
por: Dimosiari, Athina, et al.
Publicado: (2023)

Effect of Glucagon-like Peptide-1 Receptor Agonists on Cardio-Metabolic Risk Factors among Obese/Overweight Individuals Treated with Antipsychotic Drug Classes: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Patoulias, Dimitrios, et al.
Publicado: (2023)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
por: Amin, Alpesh, et al.
Publicado: (2023)

Unfractionated heparin and mechanical thromboprophylaxis in hip arthroplasty
por: Garcia, Flávio Luís, et al.
Publicado: (2015)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Pharmacologic therapeutic options for thromboprophylaxis in COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2020)

Postpartum Heparin Thromboprophylaxis: More Harm Than Good
por: Kotaska, Andrew
Publicado: (2021)

Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Cost reduction associated with heparin-induced thrombocytopenia panel ordering for enoxaparin versus heparin for prophylactic and therapeutic use: A retrospective analysis in a community hospital setting
por: Menon, Harry, et al.
Publicado: (2018)

Dose banding – Weighing up benefits, risks and therapeutic failure
por: Duffull, Stephen
Publicado: (2022)

Nanosilver: Weighing the Risks and Benefits
por: Seltenrich, Nate
Publicado: (2013)

Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients
por: McGarry, Lisa J, et al.
Publicado: (2006)

Heparin thromboprophylaxis in critically ill patients: Is it really changing outcome?
por: Gurjar, Mohan
Publicado: (2014)

A direct comparison of prophylactic low-molecular-weight heparin versus unfractionated heparin in neurosurgery: A meta-analysis
por: Macki, Mohamed, et al.
Publicado: (2019)

Therapeutic-dose anticoagulation or thromboprophylaxis with low-molecular-weight heparin for moderate Covid-19: meta-analysis of randomized controlled trials
por: Ena, Javier, et al.
Publicado: (2022)

COVID-19 convalescent plasma therapy for immunodeficient patients–weighing up risks and benefits
por: Vuk, T., et al.
Publicado: (2021)

The Anti-Factor Xa Range For Low Molecular Weight Heparin Thromboprophylaxis
por: Wei, Matthew Y., et al.
Publicado: (2015)

Multicenter study on hemorrhagic risk of heparin bridging therapy for periendoscopic thromboprophylaxis
por: Matsumoto, Mio, et al.
Publicado: (2015)

Weighing the Cost and Benefit of Transcranial Direct Current Stimulation on Different Reading Subskills
por: Younger, Jessica W., et al.
Publicado: (2016)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Heparin Thromboprophylaxis in Simultaneous Pancreas-Kidney Transplantation: A Systematic Review and Meta-Analysis of Observational Studies
por: Ai Li, Erica, et al.
Publicado: (2023)

Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial
por: Sholzberg, Michelle, et al.
Publicado: (2021)

Canadian Sex Workers Weigh the Costs and Benefits of Disclosing Their Occupational Status to Health Providers
por: Benoit, Cecilia, et al.
Publicado: (2018)

Thromboprophylaxis strategies for COVID-19 patients
por: Porres-Aguilar, Mateo, et al.
Publicado: (2022)

Weighing the costs: the epistemic dilemma of no-platforming
por: Peters, Uwe, et al.
Publicado: (2021)

Prevention strategies in clinical high-risks states for psychotic disorders: weighing up costs and benefits
por: Schultze-Lutter, F.
Publicado: (2023)

Prophylactic or therapeutic doses of heparins for COVID-19 infection? A retrospective study
por: Bolzetta, Francesco, et al.
Publicado: (2020)

Integral assays of hemostasis in hospitalized patients with COVID-19 on admission and during heparin thromboprophylaxis
por: Bulanov, Andrey Y., et al.
Publicado: (2023)

Fondaparinux Sodium Compared With Low‐Molecular‐Weight Heparins for Perioperative Surgical Thromboprophylaxis: A Systematic Review and Meta‐analysis
por: Kumar, Arun, et al.
Publicado: (2019)

Safety and Efficacy of Low Molecular Weight Heparin for Thromboprophylaxis in the Elderly: A Network Meta-Analysis of Randomized Clinical Trials
por: Yang, Hui-qin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9kl25fnr1nhcfm6cv7s0l5u7li